---
title: "Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285730549.md"
description: "Piper Sandler analyst Yasmeen Rahimi has maintained a Buy rating on Crinetics Pharmaceuticals (CRNX) with a price target of $97.00. Rahimi, who specializes in the Healthcare sector, has an average return of 33.8% and a success rate of 49.49% on her stock recommendations. The analyst consensus for Crinetics Pharmaceuticals is a Strong Buy, with a price target consensus of $86.00."
datetime: "2026-05-08T13:04:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285730549.md)
  - [en](https://longbridge.com/en/news/285730549.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285730549.md)
---

# Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals, with a price target of $97.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Rahimi covers the Healthcare sector, focusing on stocks such as Cytokinetics, Climb Bio, and LB Pharmaceuticals, Inc.. According to TipRanks, Rahimi has an average return of 33.8% and a 49.49% success rate on recommended stocks.

Crinetics Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $86.00.

### Related Stocks

- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [CLYM.US](https://longbridge.com/en/quote/CLYM.US.md)
- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)